Outcome after Surgical Resections of (recurrent) Chest Wall Sarcomas

Slides:



Advertisements
Similar presentations
CRITICAL APPRAISAL ON AN ARTICLE ABOUT PROGNOSIS
Advertisements

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
CARBON ION THERAPY FOR SACRAL CHORDOMAS
Age as a prognostic factor for head and neck squamous cell carcinoma: should older patients be treated differently? Udi Cinamon 1, Michael P. Hier 2, Martin.
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Primary thoracic sarcomas: prognostic factors and outcome in a series of patients treated at a single institution Leonardo Duranti T horacic Surgery.
Janet Eary 1, Janet O'Sullivan 3, Finbarr O'Sullivan 3, E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
Chondrosarcoma of the chest wall: primary diagnostics is decisive for outcome Björn Widhe and Henrik Bauer.
An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
CTOS years Experience of Management of Malignant Phyllodes Tumor and Breast Sarcoma at Princess Margaret Hospital Princess Margaret Hospital &
Malignancy Grade and Histologic Subtype of Primary Retroperitoneal Sarcoma (RPS) are Predictive of Pattern of Recurrence: a Large Retrospective Study from.
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,
University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.
PANCREATODUODENECTOMY + MULTIVISCERAL RESECTION YES/NO
NEOADJUVANT CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CANCER
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Liver surgery for metachronous hepatic metastases with uterine body and uterine cervix origin – a single center experience Nicolae Bacalbasa (1), Irina.
Short-term outcome of neo-adjuvant chemotherapy
Esophagectomy for cancer:
R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD
Operative Approach and
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Clinicopathological features and outcome of Head & Neck Cancer in Pakistan 1A Jamshed, 1R Hussain, 2S Jamshed, 1A A Syed, 1A Loya, 1M A Shah, 1U Majeed.
Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.
Basile Pache, Antonia Digklia*, Nicolas Demartines, Maurice Matter.
Cancer Hospital & Institute, Chinese Academy of Medical Sciences
Compassionate People World Class Care
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Multifocal myxoid liposarcoma, metastasis or second primary tumor
Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. Rastogi,S., Aggarwal, A., Soti, K.,
IMRT delivery of preoperative, high dose radiotherapy to a large volume, with Simultaneous Integrated Boost (SIB) in retroperitoneal sarcomas: The Ottawa.
Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.
Prognosis of younger patients in non-small cell lung cancer
Fig. 1c: Cystoprostatectomy specimen
HEPATIC RESECTION FOR PARENCHIMATOUS OVARIAN CANCER LIVER METASTASES BEYOND SECONDARY CYTOREDUCTION FOR RELPASED OVARIAN CANCER Nicolae Bacalbasa1,
930P - A retrospective single institution study evaluating clinical outcome and prognostic markers for endometrial and ovarian carcinosarcomas (CS) U.Asghar1,
Osteosarcoma Jessica Davis.
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Stereotactic ablative radiotherapy (SABR) versus lobectomy for operable stage I NSCLC Julia Myers.
盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全, 吳昆霖
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
Dr Jessica Jenkins Consultant Oncologist
Evaluate the results of concomitance chemoradiotherapy postoperative treatment for rectal cancer in stage II-III At K Hospital from 2012 to 2016 Speaker:
Sarcoma Wound Complications
Neoadjuvant Adjuvant Curative Palliative
The role of simultaneous resection of synchronous liver metastasis and primary colorectal cancer Samuel Lo Department of Surgery.
PRIMARY EXTREMITY STS: MULTIMODAL APPROACH MAY HAVE IMPROVED SURVIVAL
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
NAACCR/IACR Combined Annual Conference 2019
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Sternal resection and reconstruction for primary malignant tumors
Prognosis of angiosarcoma at different anatomic sites
Surgical resection of metachronous liver metastases
Presentation transcript:

Outcome after Surgical Resections of (recurrent) Chest Wall Sarcomas Is it worthwhile? Chairmen, ladies and gentleman, I would like to thank the organising commitee for the opportunity to present our data on chest wall resections for sarcoma, here in Seattle. Michael Wouters Bert van Geel Lotte Nieuwenhuis Harm van Tinteren Cees Verhoef Houke Klomp Frits van Coevorden

Resections for Chest Wall Sarcoma Background Sarcomas 1 % of all malignancies in adults 10-15% arise in the chest wall best controlled by wide (full-thickness) chest wall resections neo-(adjuvant) radio- or chemotherapy Sarcomas account for approximately one percent of all malignancies in adults. Only 10 to 15 percent arise in the chest wall. It is generally advised to perform a wide full-thickness chest wall resection, with a skeletal reconstruction and soft tissue coverage. Surgical treatment may be proceded or followed by radio- or chemotherapy.

Resections for Chest Wall Sarcoma Background / Literature   Resections for Chest Wall Sarcoma Background / Literature Author (pub.year) Study period (years) Chest wall malignancies Chest wall sarcomas Recurrent sarcomas Pfannschmidt (’06) 18 25 Gross (’05) 32 55 17 Chang (’04) 10 113 27 unknown Walsh (’01) 51 11 Sabanathan (’97) 38 49 Incarbone (’97) 13 52 19 Chapelier (’94) 9 Burt (’92) 40 126 Gordon (’91) 149 Perry (’90) 28 4 King (’86) 20 71 Pairolero (’85) 8 90 36 12 Graeber (’82) 37 59 48 In the literature few data are available regarding the appropriate management of patients with locally recurrent sarcomas on the chest wall (see the collumn on the right in this table). Most series are heterogeneous, describing resections for sarcoma as well as carcinoma, without distinguishing primary, recurrent and metastastic disease.

Resections for Chest Wall Sarcoma Background / Literature   Resections for Chest Wall Sarcoma Background / Literature Author (pub.year) Study period (years) Chest wall malignancies Chest wall sarcomas Recurrent sarcomas Pfannschmidt (’06) 18 25 Gross (’05) 32 55 17 Chang (’04) 10 113 27 unknown Walsh (’01) 51 11 Sabanathan (’97) 38 49 Incarbone (’97) 13 52 19 Chapelier (’94) 9 Burt (’92) 40 126 Gordon (’91) 149 Perry (’90) 28 4 King (’86) 20 71 Pairolero (’85) 8 90 36 12 Graeber (’82) 37 59 48 To our knowledge the largest series of recurrent sarcomas reported is the one from Gross from the cancer centre in Sao Paolo, Brasil. Their series of 55 chest wall sarcomas contained 17 patients with a local recurrence on the chest wall.

Resections for Chest Wall sarcoma Objective To evaluate: - morbidity, mortality and (disease-free) survival - outcome for primary and recurrent sarcomas of the chest wall That’s why we decided to evaluate morbidity, mortality and disease-free survival of patients surgically treated for a chest wall sarcoma, ánd to compare outcome for primary and recurrent sarcomas of the chest wall.

Resections for Chest Wall sarcoma Methods retrospective study 2 tertiary referral centers in the Netherlands 1980 – 2006 any sarcoma involving: Ribs Sternum Costo-vertebral junction Vertebral body full-thickness Chest Wall resection We conducted a retrospective study in two tertiary referral centers in the Netherlands: the Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital in Amsterdam and the Erasmus Medical Center – Daniel den Hoed hospital in Rotterdam. We identified patients surgically treated for a sarcoma of the Chest wall through the histopathologic results in file of the Pathology departments of these hospitals. The original patient files’ were retreived and only those patients with a full-thickness chest wall resection for a sarcoma involving ribs, sternum, costovertebral junction or vertebral body were selected.

Resections for Chest Wall sarcoma Full-thickness Chest Wall resection This picture shows a full thickness resection for sarcoma, including skin, a part of the latissimus dorsi, serratus muscle, intercostals as well as a partial rib resection.

Resection of Chest Wall sarcoma Patients In our study, we identified 133 patients meeting our inclusion criteria. 83 (62 percent) were treated for a primary sarcoma on the chest wall, 44 (33%) for a ‘local recurrence’. 6 patients were treated for metastases of a sarcoma on another part of the body. These patients were excluded from the study. median follow-up time: 74 months

Resections of Chest Wall sarcoma Results / Patient & Tumor characteristics PRIMARY RECURRENT Age 48 (13-81) 52 (23-75) Gender ( m – f ) 49 – 51% 45 –55 % Histology chondro/osteo liposarcoma fibrosarcoma pleiomorf leiomyosarcoma angiosarcoma other / NOS 36 (43%) 3 (4%) 11 (13%) 7 (8%) 4 (5%) 19 (23%) 13 (30%) 4 (9%) 8 (18%) 6 (14%) 2 (4%) 7 (16%) Tumor-grade low intermediate high unknown 16 (19%) 20 (24%) 31 (38%) 5 (11%) 18 (41%) 16 (36%) There were no significant differences in age, gender, co-morbidities, localization and median tumor-size of the sarcomas. Histologic types were very heterogeneous as you see in this table. The most occurring histologic subtypes were chondro- and osteosarcoma.There was no essential difference between the primary and the recurrent group.

Resections of Chest Wall sarcoma Results / Patient & Tumor characteristics PRIMARY RECURRENT Age 48 (13-81) 52 (23-75) Gender ( m – f ) 49 – 51% 45 –55 % Histology chondro/osteo liposarcoma fibrosarcoma pleiomorf leiomyosarcoma angiosarcoma other / NOS 36 (43%) 3 (4%) 11 (13%) 7 (8%) 4 (5%) 19 (23%) 13 (30%) 4 (9%) 8 (18%) 6 (14%) 2 (4%) 7 (16%) Tumor-grade low intermediate high unknown 16 (19%) 20 (24%) 31 (38%) 5 (11%) 18 (41%) 16 (36%) Also important is the similar number of high grade sarcomas in both groups.

Resections of Chest Wall sarcoma Results / Treatment characteristics PRIMARY RECURRENT Intention surgery curative palliative 81 (98%) 2 (2%) 43 (98%) 1 (2%) Neo-adj. Treatment none chemotherapy Radiotherapy 64 (77%) 17 (20%) 2 (3%) 41 (93%) 2 (5%) Skeletal resection ribs (mean number) sternum other 2.4 (0-10) 27 (32%) 16 (19%) 2.4 (0-7) 9 (20%) 10 (23%) Reconstruction mesh +/- omentum / myocutaneus flap 15 (18%) 68 (82%) 35 (80%) In the primary sarcoma group two patients, and in the recurrent group one patient had a palliative resection. In all other patients a full-thickness chest wall resection was performed with a curative intention. A minority of patients in the primary and recurrent group had pré-operative chemo or radiotherapy. A mean number of 2.4 ribs were resected in both groups. A reconstruction with any kind of mesh was performed in the majority of patients often covered by omentum or a myocutaneus flap.

Resections of Chest Wall sarcoma Results / Outcome / Morbidity PRIMARY RECURRENT Complications none bleeding infectious reconstr. failure pulm. / cardiac 66 (80%) 3 (4%) 6 (8%) 2 (2%) 9 (11%) 34 (77%) 0 (0%) 5 (11%) Re-operations number of patients 2 (5%) Hospital stay median (days) 9 12 In-hosp mortality In almost 80% of patients surgery was uneventful. Only 5% needed a re-operation, mostly for bleeding or failures of the reconstruction. Median hospital stay was 9 versus 12 days. There was no in-hospital or 30-day mortality in these groups.

Resections of Chest Wall sarcoma Results / Outcome PRIMARY RECURRENT Margins R0 R1 R2 66 (80%) 13 (16%) 3 (3%) 28 (64%) 10 (23%) 5 (11%) Recurrence no recurrence local recurrence distant recurrence 42 (51%) 20 (24%) 21 (25%) 11 (25%) 21 (48%) 12 (27%) Disease-free survival median (months) 36 18 Survival 125 55 There were more irradical resections in the recurrent than in the primary sarcoma group. This lead to a higher number of second local recurrences in this group; almost half of the patients, versus 24% in the primary sarcoma group. Therefore, disease-free survival is significantly less in the recurrent sarcoma group.

Resection of Chest Wall sarcoma Results / Outcome / DFS vs OS However, when we look at the survival curves, resection of both primary AND recurrent chest wall sarcoma translates into fair overall survival. The 5-year survival is 62% in the primary sarcoma group and 50% in the recurrent sarcoma group.

Resection of Chest Wall sarcoma Results / Outcome / Recurrences The distribution and type of recurrences in the primary and recurrent group is represented in this figure. It shows that 51% of patients in the primary group stayed disease-free during follow-up and only 25% of the recurrent group.

Resection of Chest Wall sarcoma Results / Outcome / Recurrences This difference is not due to a higher number of distant recurrences in the recurrent group, the contrary is true, the proportion of distant metastatic disease is similar.

Resection of Chest Wall sarcoma Results / Outcome / Recurrences In the group of patients operated for recurrent sarcoma, local re-recurrences occurred in 20 out of 44 patients. The contrast with the primary group in which 17 of 83 patients get a local recurrence, is considerable. Moreover, in patients with a second local recurrence in the recurrect group, MORE OFTEN a third chest wall resection was performed, namely in 12 of 20 patients against 5 of 17 in the primary sarcoma group.

Resections for Chest Wall Sarcoma Discussion Primary and Recurrent Chest Wall sarcomas have different recurrence patterns. This selection of locally recurrent Chest Wall sarcomas has less tendency to metastasize. To our opinion this difference in recurrence patterns can be explained by the biologic behaviour the tumors in the recurrent group have revealed. They are a selection of chest wall sarcomas that have shown to have less tendency to metastasize.

Resections for Chest Wall Sarcoma Conclusions Safe and effective procedure, even in locally recurrent sarcomas 5-year survival after resection of recurrent chest wall sarcomas is ‘worthwhile’! Recurrent chest wall sarcomas should be resected if technically possible. Therefore we may conclude that full-thickness chest wall resections are safe and effective procedures, even in locally recurrent sarcomas. 5-year survival is indeed worthwhile and not much less than in primary chest wall sarcomas. Thats why recurrent chest wall sarcomas without distant metastases should be resected if technically possible. THANK YOU FOR YOUR ATTENTION